Anagenics Ltd has released a press release.
Appendix 4D, Half Year Accounts and Strategy Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Anagenics
- Significant New Findings Published on Midkine
- Cellmid: Appendix 4C and Notes to Appendix 4C
- Cellmid Expects Record Sales in Q2 FY2019
- Cellmid Appoints Exclusive New Zealand Distributor
- New Patents for Midkine Antibodies in USA and Europe
Later from Anagenics
- Minimum Holding Share Buy-Back
- Cellmids Evolis Registered in European Union (EU)
- Cellmid Sets Another Sales Record in Q4 FY2019
- Response to Appendix 4C Query
- CDY Signs Distribution Agreement for EVOLIS in South Korea
Follow Anagenics into a list and get an email when it puts out news.
Follow Anagenics